Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock

After Eli Lilly and Co (NYSE: LLY) earlier announce the failure of its Alzeheimer’s candidate solanezumab, the entire Alzheimer's sector could feel the aftershocks. While some of the players have since recovered from early morning drops, a few are still in the red in early Wednesday afternoon.

Alzheimer's Treatment Stocks

Below are the players within the sector, and their subsequent stock movements at time of writing:

• AC Immune Ltd (NASDAQ: ACIU): Down 16.06 percent at $11.50.
• Alkermes Plc (NASDAQ: ALKS): Up 0.69 percent at $58.74.
• Anavex Life Sciences Corp. (NASDAQ: AVXL): Up 6.76 percent at $3.63.
• Biogen Inc (NASDAQ: BIIB): Down 3.94 percent at $305.59.
• Eli Lilly and Co: Down 10.76 percent at $67.82.
• Neuralstem, Inc. (NASDAQ: CUR): Up 3.81 percent at $0.270.
• Novartis AG (ADR) (NYSE: NVS): Up 0.98 percent at $68.76.
• Roche Holding Ltd. (ADR) (OTC: RHHBY): Down 1.3 percent at $27.40.